CA-GENERAL-ATOMICS
6.1.2020 22:02:13 CET | Business Wire | Press release
General Atomics Aeronautical Systems, Inc. (GA-ASI) concluded a series of flight demonstrations using its MQ-9 Guardian Remotely Piloted Aircraft System (RPAS) on December 19, 2019. The demonstrations showcased the maritime surveillance capabilities of the MQ-9, and the GA-ASI-developed Detect and Avoid (DAA) system for traffic-deconfliction in civil airspace. The flights were sponsored by the Hellenic Air Force (HAF) and the Hellenic Coast Guard (HCG) and staged out of Larissa Air Base in Greece. The flights were performed for an audience of European military and civilian representatives.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200106005949/en/
“We were honored to have the HAF’s and the HCG’s support for these flight demonstrations with our MQ-9,” said Linden Blue, CEO, GA-ASI. “The MQ-9 RPAS is already a strategic asset for NATO countries, providing mission persistence and interoperability between allies. We showcased MQ-9’s maritime surveillance and the civil airspace integration capabilities for our European customers.” The MQ-9 configuration demonstrated is operational in the U.S.
Currently GA-ASI aircraft systems support the Italian Air Force, the UK Royal Air Force, the French Air Force, and the Spanish Air Force. The Ministry of Defence for the Netherlands has selected MQ-9 for the Royal Netherlands Air Force, and the Government of Belgium has approved Belgian Defense to negotiate the acquisition of GA-ASI’s MQ-9B. In early December, the Australian Government announced selection of MQ-9B for the Australian Defence Force under Project Air 7003. GA-ASI RPAS are operated by the U.S. Air Force, U.S. Army, U.S. Marine Corps, U.S. Department of Homeland Security and NASA.
“The advanced capabilities of these aircraft are striking. Through the 10 days of demonstrations, the country of Greece has seen the value of MQ-9s for maritime patrol and EEZ monitoring, border surveillance, support for search and rescue efforts, and over-watch of forest fire response efforts,” said an HAF official.
The DAA system consists of an air-to-air radar integrated with Traffic Alert and Collision Avoidance System (TCAS II), and Automatic Dependent Surveillance-Broadcast (ADS-B). The DAA system enables safe flight of an MQ-9 in civil airspace, and can even detect air traffic that is not actively transmitting its position.
The MQ-9 also demonstrated a multi-mode, maritime surface-search radar, and High-Definition/Full-Motion Video Optical and Infrared sensor. This sensor suite enables real-time detection and identification of large and small surface vessels in all-weather at long ranges, 360 degrees around the aircraft. The featured Raytheon SeaVue surface-search radar provided continuous tracking of maritime targets and correlation of AIS transmitters with radar detections. The Inverse Synthetic Aperture Radar (ISAR) mode facilitates classification of vessels which are beyond optical sensor range.
For the demonstration, GA-ASI partnered with SES, a leading satellite communications (SATCOM) operator and managed services provider, with over 70 satellites in Geostationary Orbit (GEO) and Medium Earth Orbit (MEO). SES provided the GEO satellite connectivity that enabled the MQ-9 to operate securely with a high capacity datalink, enabling real-time transmission of sensor data from the aircraft, and extending its effective operational range far beyond that of “line-of-sight” datalinks.
“With our global satellite fleet, SES has been supporting the critical needs of GA-ASI and their government customers who have operated these aircraft for close to two decades,” said Nicole Robinson, Senior Vice President, Global Government at SES Networks. “We were proud to support this demonstration effort for the Hellenic Air Force as part of our long-standing relationship with General Atomics.”
Hi-resolution images from the demonstration are available to qualified media outlets from the GA-ASI and HAF media contact list. More information about the event is available at www.ga-asi.com/european-maritime-demo .
About GA-ASI
General Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable Remotely Piloted Aircraft (RPA) systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than six million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent flight that enables situational awareness and rapid strike. The company also produces a variety of ground control stations and sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas. For more information, visit www.ga-asi.com .
Predator and Lynx are registered trademarks of General Atomics Aeronautical Systems, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200106005949/en/
Contact:
Steven Henden General Atomics Aeronautical Systems, Inc. +1 (858) 524-8101 ASI-MediaRelations@ga-asi.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
Unpack ’26 sommerrejsetrends: Flere vælger indenlandske rejser, når de tænker mere bevidst over deres rejsevalg21.5.2026 12:35:00 CEST | Pressemeddelelse
Rejsebranchens førende databrevne trendrapport lancerer sin første sommerudgave nogensinde – Unpack ’26 Summer: The Trends in Travel I dag har Hotels.com udgivet Unpack ’26 Summer: The Trends in Travel, den nyeste udgave af virksomhedens førende trendrapport i rejsebranchen, som viser, hvordan rejseadfærd former sommerens rejsevalg. Efterspørgslen på indenlandske rejser præger sommerens ferieplanlægning. Interessen på sociale medier for indenlandske ferier er globalt steget med 77% sammenlignet med sidste år, og 44% af danske rejsende planlægger en indenlandsk rejse denne sommer*. Fra store sportsbegivenheder og koncerter til rejser inspireret af film og tv bygger Unpack ’26 Summer på indsigter fra den årlige hovedrapport Unpack ’26: The Trends in Travel™ for at fremhæve, hvor rejsende tager hen denne sommer. HHver tendens bygger på førstehåndsdata fra Hotels.com® kombineret med indsigter fra rejsende og overvågning af sociale medier. “Denne sommer bliver der stadig rejst – men på nye
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 12:30:00 CEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
Cognite and ABB Collaborate to Integrate Agentic AI into Industrial Applications to Deliver Faster Workflows21.5.2026 12:00:00 CEST | Press release
Aker BP joins as the first customer to scale agent-to-agent operations through a new generation of industrial agentic workflow applications Cognite, the leader in Industrial AI, today announced a collaboration with ABB to assess how advanced industrial AI and data capabilities can be integrated to solve key use cases in the energy sector. By adding an agentic layer to established industrial applications, including ABB Ability™ SafetyInsight™ and ABB Ability™ AlarmInsight™, using the Cognite Industrial AI and Data platform, the collaboration aims to enable "agent-to-agent" orchestration. Leading energy producer Aker BP has signed on as the first customer to implement this new generation of intelligent offerings as part of its strategy to further increase its current production efficiency of 96% and achieve a production growth target of 525,000 barrels of oil equivalent per day by 2028. Transforming Data into Actionable Business Value By breaking down traditional data silos and shifting
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts21.5.2026 12:00:00 CEST | Press release
Long-term and real-world evidence reinforce BRUKINSA as the foundation of CLL treatmentThree oral presentations at ASCO highlight rapid acceleration of BeOne’s solid tumor pipeline BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and solid tumors have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago) and the 2026 European Hematology Association (EHA) Congress (June 11–14, Stockholm). Continuing to raise the bar in CLL At ASCO and EHA 2026, BeOne will showcase its hematology leadership with data spanning foundational therapies and next-generation innovation across CLL, mantle cell lymphoma and other B-cell malignancies. The data emphasize impressive long-term outcomes, durability across patient populations, and a disciplined approach to advancing future regimens. Collectively, these data undersco
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
